Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
about
Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.Optimal treatment of poor-risk renal cell carcinoma patients with mTOR inhibitors and anti-VEGFR agents.First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.Synergistic antitumor activity of low-dose c-Met tyrosine kinase inhibitor and sorafenib on human non-small cell lung cancer cells.Immune consequences of anti-angiogenic therapyin renal cell carcinoma.
P2860
Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Efficacy of sorafenib in advan ...... histology or prognostic group.
@ast
Efficacy of sorafenib in advan ...... histology or prognostic group.
@en
type
label
Efficacy of sorafenib in advan ...... histology or prognostic group.
@ast
Efficacy of sorafenib in advan ...... histology or prognostic group.
@en
prefLabel
Efficacy of sorafenib in advan ...... histology or prognostic group.
@ast
Efficacy of sorafenib in advan ...... histology or prognostic group.
@en
P2093
P2860
P356
P1476
Efficacy of sorafenib in advan ...... histology or prognostic group.
@en
P2093
Ali Tafreshi
Eddy Thientosapol
Ian D Davis
Melissa Quaggiotto
Mun Sem Liew
P2860
P356
10.1111/AJCO.12122
P50
P577
2013-10-24T00:00:00Z